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Acute hepatic failure was induced in rats by galactosamine injection intraperitoneally (1 gm per 
kg). Twenty-four hours later rats were treated by hemoperfusion (HP) over encapsulated sorbents: 
cellulose acetate-coated charcoal, polyelectrolyte-coated XAD4, a combination of both, or cross 
circulation with a healthy donor. Compared with control treatment (prevention of hypoglycemia 
by glucose infusion), the survival rate was not improved by HP or cross circulation: controls 19% 
vs. treated animals 0 to 17%. Extension of duration or increased frequency of HP gave the same 
survival rates. Computer simulation based on zero-order introduction of a possible toxin into a 
two-compartment model shows that HP up to 5 hr per day is not able to clear the body effectively 
from the assumed toxin if its partition coefficient exceeds a value of 50. 
It is generally assumed that hepatic encephalopathy 
(HE) can be caused by a detrimental negative effect of a 
changed plasma composition on normal brain function 
(1). 
Although progress in the study of objective quantifi- 
cation of brain malfunction certainly will improve our 
understanding of the pathogenesis of HE in the near 
future (2), the clinician cannot wait and watch the pa- 
tient in the mean time. Many different techniques of 
clearing the blood of possible toxic substances and waste 
metabolites have been applied, varying from exchange 
transfusion to hemoperfusion (HP) (3). 
In 1972, Chang (4) reported recovery of consciousness 
in Grade IV hepatic coma in man after charcoal HP 
treatment. Extension of this treatment to 56 patients 
showed no conclusive evidence of its beneficial effect 
partly due to the lack of controlled trials (5 ) .  
In 1981, Chang (6) published survival rates of fulmi- 
nant hepatic failure in rats with severe galactosamine 
(Gal-N) hepatitis. During Grade I1 hepatic coma, sur- 
vival rates improved significantly by HP over albumin- 
coated activated charcoal (ACAC) and by in situ homol- 
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ogous liver perfusion. In Grade 111 coma, ACAC HP had 
no beneficial effect. 
Further improvement of survival rates could possibly 
be realized by an increase of the frequency of HP and/ 
or changing the type of adsorbent (XAD,, a neutral resin 
with high affinity for fat-soluble compounds or a com- 
bination of charcoal and XAD4). Therefore, we decided 
to study the effect of these different types of HP in rats 
with severe Gal-N-induced hepatitis. As a reference, 
cross circulation with a healthy inbred donor rat was 
applied. 
MATERIALS AND METHODS 
ANIMALS 
Male Wistar rats (TNO, Zeist, The Netherlands), 
weight 300 to 350 gm, were maintained on an unrestricted 
commercial diet (Hope-Farms). Twenty-four hours be- 
fore Gal-N administration, rats were starved for 24 hr. 
After Gal-N administration, food and liquid (10% glu- 
cose) were available ad libitum. If spontaneous drinking 
stopped, 5% glucose was administered intraperitoneally 
or subcutaneously (5  to 10 ml per 24 hr). 
SORBENTS 
Activated charcoal (Norit RBXI) coated with cellulose 
acetate (CA) (4 gm per kg) (Tijssen et al.) (7), Amberlite 
XAD, (Serva, Heidelberg, West Germany) coated with 
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either cellulose acetate (6 gm per kg) or polyelectrolyte 
(PLE) were as described by De Koning et al. (8). 
Gal-N HC1 (Merck, Darmstadt, West Germany), a 
solution of 100 mg per ml, was freshly prepared in sterile 
water and neutralized at pH 7.4 just prior to intraperi- 
toneal injection at  a dosage of 1 gm per kg. 
ANALYTICAL PROCEDURES 
SGPT, glucose, and platelet counts were measured 
according to standard laboratory techniques in clinical 
chemistry. 
A-V SHUNT OPERATION 
In order to  assess extracorporeal circulation, a shunt 
[vein-catheter (0.5 x 0.9 mm), B. Braun, Melsungen, 
West Germany] was applied from the carotid artery to 
the contralateral jugular vein under pentobarbital anes- 
thesia (50 mg per kg). 
HP SYSTEM 
The H P  system is shown schematically in Figure 1. 
Arterial blood is pumped by a small roller pump (Wat- 
son-Marlow) to the H P  column, through which it flows 
in an antigravity manner. After passage of the bubble 
catcher, the blood flows to the venous side of the shunt 
back into the circulation. 
The total system is maintained at 37°C in a water bath 
and connected by silastic tubing I.D. 0.062, O.D. 0.095 
inch. The priming volume of the whole system is about 
4 ml, and each H P  column contains either 2.7 gm of 
encapsulated coal or 1.8 gm of encapsulated XAD,. In 
the column, the sorbent is covered by two nylon filters 
and two PMMA support screens. 
HP PROTOCOL 
Prior to use, the system is recirculated by a heparin- 
glucose solution (100 ml 5% glucose, 500 units heparin) 
for about 30 min. Then, the system is primed with 4 ml 
U 
FIG. 1. Schematic drawing of the HP system. Blood is recirculated 
extracorporeally from the right carotid artery to the left jugular vein 
by a roller pump and flows through the column in an antigravity 
manner. The column is filled with approximately 3 gm of the encap- 
sulated sorbent. A bubble catcher is placed between the column and 
the jugular vein. If neded, heparin can be infused. The whole HP 
system is thermostated at 37’C in a water bath and connected by 
silastic tubing I.D. 0.062, O.D. 0.095 inch. During HP, the rat is awake 
and kept in a restraining age (not drawn). 
fresh heparinized (2 units per ml) rat blood (donor rat of 
the same strain). Except for the priming volume, no 
additional heparin is used during HP. 
Under ether anesthesia, the shunt of the “patient rat” 
is opened and before both sides are connected to the HP 
system, 1.5 ml of arterial blood is collected for analysis 
(SGPT), glucose, and platelets). A roller pump provides 
a flow rate of 2 ml per min. 
After finishing HP again, a 1.5-ml blood sample is 
taken; the rat receives about 3 ml donor blood, and the 
shunt is restored. During the HP period, the rat is awake 
and kept in a restraining cage permitting only forward 
and backward movements over about 5-cm distance. 
Arterial blood pressure is measured at  regular intervals 
(10 min) by a pressure transducer connected to the 
arterial line close to the carotid artery. 
TIME SCALE 
At time zero, an A-V shunt is implanted during pen- 
tobarbital anesthesia and Gal-N is given intraperito- 
neally. The rat is allowed food and 10% glucose ad 
libitum. Twenty-four hours later, H P  is applied as indi- 
cated previously. Control animals undergo the same pro- 
cedure but now H P  is applied with a column filled with 
heparinized fresh rat blood (no adsorbent). 
CROSS CIRCULATION 
During the morning of the day of cross circulation, the 
donor rat receives an A-V shunt as described previously. 
During either anesthesia, without heparinization, the 
patient rat is connected to the donor rat; the last remains 
anesthesized by pentobarbital (50 mg per kg) and is 
placed on a scale. A roller pump is connected in between, 
and the flow rate is set a t  2 ml per min. The weight of 
the donor is checked continuously and speed of in- or 
outflow is corrected if necessary. 
COMPUTER SIMULATION PROGRAM 
A Minc-11 (TM), 8-bit mini-computer of the PDP-11 
series designed for laboratory support was used con- 
nected with a LA 38 matrix printer, producing 30 char- 
acters per second. A simulation program describing a 
two-compartment model, based on linear differential 
equations as are used in pharmacokinetics (9), was writ- 
ten by one of us (R. P.) (see Figure 2). Assuming relative 
concentration differences to be the driving force of trans- 
port by diffusion between the two compartments, the K P I  
was calculated from the K12 by the ratio of the surface 
interaction of the two postulated compartments [For- 
mula (v)]. 
The program calculates changing plasma concentra- 
tion, total body stock, patients’ elimination, and HP 
elimination for the following variable parameters: 
Po = zero-order production rate in units per hour; 
KI2 = transfer rate from 1st to 2nd compartments; 
V1 = real central volume (liters); 
V2 = real peripheral volume (liters); 
Q1 = partition coefficient of the toxin; 
Klo = patients own elimination rate; 
C = clearing factor of the column (%); 
F2 = flow through the column (liters per min); and 
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T = perfusing time (hours). 
Without HP, the differential equations are: 
(i) For the central compartment (Vl) 
-- - Po + KziXz - KizXi - Ki& a1 dt 
X(ik stands for the total stock in the compartment 
in concern. 
If 
(ii) For the peripheral compartment (V,) 
- K12X1- KziXz. -- a 2  dt 
(iii) During HP, Formula (i) changes in 
-- a1 - Po + KziXz - KiZXi - KioXI - KCXI. 
dt 
The elimination rate of the column (KJ is cal- 
culated by Formula (iv). 
TABLE 1. SURVIVAL OF HEALTHY CONTROL RATS AFTER HP 
-~ ~ ~~~ 
Platelet loss” (%) Survival rate 
(mean f S.D.) (>14 days) Adsorbent 
~~ -~ 
COAL-CA 5 50 f 2 100% (5/5) 
XAD4-CA 2 16 100% (2/2) 
XADI-PLE 4 15 f 33 100% (4/4) 
COAL-CA and XAD4-PLE 4 21 f 10 100% (4/4) 
Expressed as a percentage of the initial amount. 
(v) Kzl = K12 VW. Qi’V2 
RESULTS 
HP OF HEALTHY CONTROLS 
Table 1 shows the effect of HP through various coated 
sorbents on survival and platelet loss of healthy rats. 
The HP “treatment” was initiated 24 hr after provision 
of the A-V shunt and was continued for 1 hr. It can be 
seen that blood compatibility was reasonable, and sur- 
vival was 100% in all cases. Systolic blood pressure varied 
between 120 to 140 mm Hg, and no severe hypotension 
was observed. 
HP OF GAL-N RATS 
Table 2 shows the effect of HP with different adsor- 
bents on survival rate of severe Gal-N hepatitis. No 
beneficial effect on survival by either treatment could be 
observed. Most rats died within 2 to 3 days after Gal-N 
injection. Even repeating HP 3 times over COAL-CA did 
not improve survival rate. 
CROSS CIRCULATION 
Cross circulation for 1 or 2 hr initiated 24 hr after Gal- 
N injection did not improve survival rate as shown in 
Table 3. 
COMPUTER SIMULATION 
Figure 3 shows the computer simulation of the effect 
of HP for 5 hr on the plasma concentration and total 
body amount of a postulated “toxin”. It is evident that if 
TABLE 3. SURVIVAL OF SEVERE GAL-N RATS 
Treatment“ (mean +_ S.D.) (>14 days) 
SGPTb (units/liters) Survival rate 
19% (6/31) 
n 
Controls 31 1,835 .+ 1,350 
Cross circulation 11 3,200 2 1,300 0% (0/11) 
(1 hr) 
(2 hr) 
Cross circulation 6 2,422 +- 808 17% (1/6) 
“Cross circulation with a healthy donor of the inbred strain was 
carried out 24 hr after Gal-N injection (1 gm/kg). 
Measured 24 hr  after Gal-N injection. 
TABLE 2. SURVIVAL OF SEVERE GAL-N HEPATITIS 
Survival rate 
Controls 31 1,835 * 1,350 ND’ 19% (6/31) 
COAL-CA HPd 17 2,045 f 970 19 f 12 6% (1/17) 
0% (0/6) XAD4-CA HPd 6 3,000 f 2,200 35 k 17 
XAD,-PLE HPd 6 2,300 +- 2,040 60 f 7 0% (0/6) 
COAL-CA + XAD4-PLE HPd 7 1,900 f 1,420 21 f 10 0% (0/7) 
COAL-CA HP ( 3 ~ ) ‘  5 3,625 f 3,720 ND‘ 0% (0/5) 
SGPT” (units/liter) Platelet lossb (%) 
Treatment n (mean i S.D.) (mean i S.D.) (>14 days) 
a Measured 24 hr after Gal-N injection. 
‘ ND, not determined. 
‘ HP was carried out for 60 min at time 24, 29, and 48 hr after Gal-N injection (1 gm/kg). 
Expressed as a percentage of the initial amount. 
HP was carried out for 60 min at time 24 hr after Gal-N injection (1 gm/kg). 
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the toxin dissolves equally in water and fat (partition 
coefficient of L O ) ,  a H P  column with a clearing factor of 
100% is very well able to reduce the total body stock of 
the toxin in a relatively short time. 
Figure 4 shows the same simulation but now toxins 
with a postulated partition coefficient of 50 and 100, 
respectively, are depicted. Total body stock is hardly 
influenced. 
Table 4 shows the elimination capacity of HP for 5 hr 
over a 100% effective column in relation to different 
compartment volumes, different partition coefficients, 
and different transfer rates of compartment 1 to com- 
partment 2 (KI2). Assuming one (arbitrarily chosen) 
standard body stock value (480 units) a t  the start of HP, 
elimination capacity of more than 50% is only obtained 
at  partition coefficients lower than 25 if V2 is 40 liters 
and at a partition coefficient lower than 50 if V p  is 16 
liters. 
DISCUSSION 
The results of H P  in healthy controls show that bio- 
compatibility of the procedure is very acceptable. This is 
in agreement with the in uitro results of blood compati- 
bility as reported by De Koning (10). In Gal-N hepatitis 
rats, no fatal effect of HP could be observed on blood 
compatibility and arterial blood pressure under our ex- 
perimental conditions. Postmortem microscopic inspec- 
tion of liver, heart, lungs, and kidney showed no other 
abnormalities than those contributable to severe Gal-N 
hepatitis as described by Decker and Keppler (11). 
SIMULATION HEMOPERFUSION (H.P 1 
(Po=lO U/hr , K1,=Ol;V1=14L; V2=16L;C&l; K1o.O ;C=lOO%) 
H P  H P  H P  tip 
start stop start stoD 
I 
0 4e‘ 54 $2 715 
Time (hrs . )  
FIG. 3. Computer simulation of H P  effect on total body stock and 
plasma concentration of the “toxin”. At time 0, zero order production 
rate starts at 10 units per hr. K,,, 0.1. Elimination rate of the patient 
is 0. Central volume (V,) is 14 liters. Peripheral volume (V,) is 16 liters. 
Partition coefficent (Q, )  is 1. Flow through the column: 0.5 liter per 
min. Clearing factor of the column (C) is 100%. Perfusion time is 5 hr. 
SIMULATION HEMOPERFUSION 
(P,=lOU/hr ;K12=0.1. V1=14L, V2=16 L .  Kl,,=O. C=lOO%) 
H P  H P  H P  H P  
start stoD start stoD 
401 20 I ’!I 2 
62 67 75 
Time (hrs .  
FIG. 4. Computer simulation of H P  effect on total body stock and 
plasma concentration of the “toxin”. At time 0, zero order production 
rate starts at 10 units per hr. KI2 is 0.1. Elimination rate of the patient 
is 0. Central volume (V,) is 14 liters. Peripheral volume (V,) is 16 liters. 
Two different partition coefficients (Q1) are shown: 50 and 100. Flow 
through the column is 0.5 liter per min. Clearing factor of the column 
(C) is 100%. Perfusion time is 5 hr. 
TABLE 4.COMPUTER-SIMULATED ELIMINATION CAPACITY OF HP 
Column elimination capacity” (%) 
Vl = 14 and V, = 16 liters 
0.01 90 47 33 25 20 
0.10 97 74 55 40 29 
0.40 98 79 60 45 32 
Vl = 14 and V, = 40 liters 
0.01 15 33 23 18 15 
0.10 93 55 36 26 18 
0.40 95 60 41 29 20 
Defined as per cent of the postulated total body stock of the toxin 
at 53 hr if no HP had been applied. PO, 10 units/hr; H P  is started after 
48 hr; KIO, 0; C, 100%; FB, 0.5 (liter/min); T, 5 hr; Q1, partition 
coefficient of the toxin. 
Our results show no beneficial effect on survival rate 
from severe Gal-N hepatitis neither by HP over encap- 
sulated sorbents (coal, XAD4, or a combination of both) 
neither by cross circulation. This is in agreement with 
the results of Chang et al. (6, 12-14) as far as Grade 111 
coma rats are concerned, although they use a slightly 
different methodology (Gal-N dosage, 1.1 gm per kg and 
starting H P  at a time of 48 hr). Since under our experi- 
mental conditions almost all animals reach coma Grade 
I11 at about 48 hr and do not survive a period of more 
than 50 to 55 hr, our rats cannot be compared with 
Chang’s favorable results in Grade I1 coma rats. Fur- 
thermore, since it is a common experience that big dif- 
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ferences in survival rate can exist between batches of 
animals with the same high dose of Gal-N (14), the 
conclusion seems justifiable that rats in coma Grade I1 
at 48 hr after Gal-N injection belong to a “privileged 
category. 
If HP were able to improve survival rate of Grade 
I11 coma rats, starting this treatment a t  24 hr instead of 
at 48 hr after Gal-N injection would increase rather than 
decrease survival rate, extrapolating the recent results of 
Gimson et al. in human fulminant hepatic failure (15). 
On theoretical grounds, however, it seems very unlikely 
that HP or cross circulation for 1 or 2 hr a day will be 
sufficient to replace effectively the failing detoxification 
function of acute hepatic failure when accumulation of 
toxic factors most probably occurs continuously. In favor 
of this idea is the reported evidence that long-term 
treatment (e.g., hemofiltration) has improved conscious- 
ness in patients (16). 
Our results obtained by computer simulation show 
clearly that HP is only effective in removing toxic sub- 
stances with a small distribution volume (low partition 
coefficient) and that the outcome is hardly influenced by 
rather large changes in transfer rates (KI2 and Kz1) 
between the two compartments (Table 4). This is in 
agreement with the computer simulation of hemoperfu- 
sion by Berk (17) applied to unconjugated bilirubin. His 
data show that even if 50% of the total body stock of the 
presumed “toxin” (unconjugated bilirubin) is present in 
the central volumes (plasma), a 3-day period of 4-hr HP 
each day is needed before normal plasma values are 
obtained. These results are quite comparable with our 
calculation of a “toxin” with a partition coefficient of 
about 1.0 (Figure 3). Although strong binding of the 
presumed “toxin” to albumin hampers significantly the 
efficacy of HP treatment (18, 19), a high partition coef- 
ficient of the “toxin” is a far more restrictive factor for 
success of this type of treatment. 
Since hepatic biotransformation concerns especially 
metabolic waste products with low polarity, high-protein 
binding, and/or high-fat solubility, it seems very likely 
that potential comagenic factors in HE will have a high 
partition coefficient. Considering this, we are not sur- 
prised that intermittently applied HP for a relatively 
short time is not a successful treatment of severe hepatic 
failure. 
Therefore, we suggest that an important feature of 
artificial support of the failing hepatic detoxification 
function should be efficiency in removing substsances 
with a high partition coefficient. Such an artificial liver 
support will certainly be more successful if it can be 
applied in an early phase of acute hepatic failure and if 
it can be given continuously. 
Peritoneal dialysis has more or less these characteris- 
tics depending on the composition of the dialysate. Ex- 
periments are in progress to test this hypothesis. 
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